Payment overview · 2025
General Payments
$1,937.53
45 reported records · 10 companies
Healthcare provider profile · identity verified
Stephen E. Wilson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CINCINNATI, OH · NPI 1760430953
Verified facts
What the public records show
CMS Open Payments records show Stephen E. Wilson, M.D. received $1,937.53 in general payments during 2025 across 45 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $423.89 | 21.9% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $368.43 | 19.0% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $246.43 | 12.7% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $241.79 | 12.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $219.06 | 11.3% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $186.49 | 9.6% | 10 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $119.89 | 6.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $88.92 | 4.6% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.83 | 1.1% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $20.80 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,937.53 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $241.79 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $206.91 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $178.75 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $161.09 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $158.29 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $142.88 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $135.89 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $121.19 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $119.89 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $119.61 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $116.54 | 5 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $88.92 | 5 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $62.98 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $47.22 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $37.46 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.73 | 2 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $34.35 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 92 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 77 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 97 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
92 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
97 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 533 | 135 |
| Amlodipine Besylate | Amlodipine Besylate | 339 | 95 |
| Metformin Hcl | Metformin Hcl | 206 | 55 |
| Gabapentin | Gabapentin | 147 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 138 | 47 |
| Lisinopril | Lisinopril | 135 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 135 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 133 | 44 |
| Trazodone Hcl | Trazodone Hcl | 131 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 130 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 43 |
| Omeprazole | Omeprazole | 128 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 127 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 124 | 33 |
| Carvedilol | Carvedilol | 118 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 118 | 38 |
| Furosemide | Furosemide | 114 | 32 |
| Jardiance | Empagliflozin | 105 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 103 | 29 |
| Trulicity | Dulaglutide | 101 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 97 | 18 |
| Losartan Potassium | Losartan Potassium | 93 | 31 |
| Farxiga | Dapagliflozin Propanediol | 92 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 20 |
| Ozempic | Semaglutide | 77 | 18 |
| Aripiprazole | Aripiprazole | 71 | 14 |
| Simvastatin | Simvastatin | 68 | 18 |
| Valsartan | Valsartan | 68 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 64 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 64 | 18 |
| Allopurinol | Allopurinol | 62 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 60 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 18 |
| Prednisone | Prednisone | 59 | 26 |
| Spironolactone | Spironolactone | 56 | 18 |
| Montelukast Sodium | Montelukast Sodium | 53 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | 12 |
| Atenolol | Atenolol | 44 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 44 | 16 |
| Meclizine Hcl | Meclizine Hcl | 42 | 16 |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Azithromycin | Azithromycin | 41 | 38 |
| Oxycodone Hcl | Oxycodone Hcl | 40 | suppressed |
| Potassium Chloride | Potassium Chloride | 40 | 11 |
| Sertraline Hcl | Sertraline Hcl | 40 | 12 |
| Alendronate Sodium | Alendronate Sodium | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 12 |
| Ezetimibe | Ezetimibe | 39 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 37 | suppressed |
| Naproxen | Naproxen | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 19 |
| Famotidine | Famotidine | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Linzess | Linaclotide | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | 11 |
| Lorazepam | Lorazepam | 28 | 11 |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 13 |
| Eliquis | Apixaban | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Ibuprofen | Ibuprofen | 23 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Meloxicam | Meloxicam | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | suppressed |
| Cefdinir | Cefdinir | 18 | 16 |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 15 |
| Finasteride | Finasteride | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Rufinamide | Rufinamide | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Klor-Con M10 | Potassium Chloride | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,937.53 · 45 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, BEXSERO, BREZTRI, COMIRNATY, FARXIGA, FREESTYLE LIBRE 3, Kerendia, LEQVIO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, SHINGRIX, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error